Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
Solid Biosciences has dosed the first participant in its Phase 3 IMPACT DUCHENNE trial evaluating SGT-003 for Duchenne muscular dystrophy, a randomized, placebo-controlled study designed to support potential accelerated approval. The Phase 1/2 INSPIRE DUCHENNE trial has now dosed 46 participants with SGT-003, which has been generally well tolerated with no observed cases of serious adverse events like drug-induced liver injury or myocarditis.
Key figures
- Drug Name
- SGT-003
- Phase Of Trial
- Phase 3
- Disease prevalence us
- 10,000 to 15,000 cases
- Trial primary endpoint
- change from baseline at 18 months in time to rise from supine (TTR) velocity
- Participants dosed phase1 2
- 46
- Participants dosed phase1 2 year end 2025
- 30
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.